The greatest benefit of the addition of an SGLT2 inhibitor to standard therapy in patients with heart failure was a 28% relative reduction in the risk of hospitalization for heart failure, with an NNT of 28 to prevent one event over a follow-up of 23 months. Here, SLC5A2 is linked to heart failure.